Agenus | AGEN - Net Income


Agenus reported $-10.63M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Agenus USD -10.63M 74.49M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
CSL USD 401M 96.5M Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
J&J USD 5.24B 119M Mar/2026
Jiangsu Hengrui CNY 1.96B 658.82M Dec/2025
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Merck EUR 319M 583M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Northwest Biotherapeutics USD -27.18M 7.81M Sep/2025
Novartis USD 2.41B 1.52B Dec/2025
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Veracyte USD 41.15M 22.01M Dec/2025